Table 1.

Epidemiological characteristics and HIV immunovirological status of the study patients by gender

	All patients (n=97)	Male group (n=45)	Female group (n=52)	p-value
Median age1 (years)		26 (24-27)	26 (25-27)	25 (24-27)	0.97
Current smoker, no. of patients2		34 (35.1%)	20 (44.4%)	14 (26.9%)	0.071
Co-infections2	HBV	30 (32%)	10 (22.2%)	21 (40.4%)	0.056
	HCV	3 (3.2%)	2 (4.4%)	1 (1.9%)	0.47
HBV + HDV	2 (2.1%)	2 (4.5%)	0	0.12
Median BMI1 (kg/m2)		21.3 (18.5-23.5)	22.8 (19.5-24)	20.4 (18-22. 4)	0.015*
Nutritional status2,	Underweight	23 (23.7%)	9 (20%)	14 (26.9%)	0.42
	Overweight	12 (12.4%)	7 (15.6%)	5 (9.6%)	0.34
Obese	2 (2.1%)	2 (4.4%)	0	0.12
Mean time from HIV diagnosis3, years		16.7 ± 4.54	17.9 ± 3.94	15.8 ± 4.82	0.024*
Median ART schemes1		5 (3-6)	5 (2-7)	4.5 (3-6)	0.74
Median time of exposure to ART1, years		15 (12-17)	15 (13-17)	14 (11.8-16.3)	0.34
PI treatment2		87 (89.7%)	42 (93.3%)	45 (86.5%)	0.27
Median PI exposure time1, years		9 (5-13)	10 (8-14)	7.5 (8-13)	0.06
EFV treatment, no. of patients2		57 (58.8%)	26 (57.8%)	31 (59.6%)	0.85
Median EFV exposure time1, years		2 (0-6)	2 (0-5)	1 (0-7)	0.66
TDF treatment2		13 (13.4%)	3 (6.7%)	10 (19.2%)	0.07
HIV plasma viral load categories2, copies/mL	Undetectable	60 (61.9%)	28 (62.2%)	32 (61.5%)	0.94
	< 200	17 (17.5%)	6 (13.3%)	11 (21.2%)	0.31
> 200	20 (22.7%)	11 (24.4%)	9 (17. 3%)	0.38
Median CD4 level1, cells/mm3	365 (299-746)	552 (246-801)	513 (319-696)	0.87
CD4 cell categories2, cells/mm3	> 500	53 (54.6%)	26 / 57.8	27 / 51.9	0.564
	200 - 499	33 (34%)	11 (24.4%)	23 (44.2%)	0.042*
< 200	10 (10.3%)	8 (17.8%)	2 (3.8%)	0.024*

¹Median (interquartile range)

²Number/percent; 3Mean ± standard deviation;

^*p ≤ 0.05, BMI – body mass index, ART – antiretroviral treatment, PI – protease inhibitors, EFV – Efavirenz, TDF tenofovir disoproxil fumarate.